Life Science Investing ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer 12 September
Life Science Investing ALX Oncology to Participate in Upcoming Investor Conferences in September 29 August
Life Science Investing ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors 19 August
